UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

Form 8-K

Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 10, 2006

 

Metabasis Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

 

Registrant’s telephone number, including area code: (858) 587-2770

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 2.02               Results of Operations and Financial Condition.

On August 10, 2006, we announced financial results for the second quarter ended June 30, 2006 in the earnings release attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 2.02 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.  The information in this Item 2.02 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 9.01               Financial Statements and Exhibits.

(d)           Exhibits.

99.1         Press release of Metabasis Therapeutics, Inc. dated August 10, 2006.

 

 

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                                                                                       METABASIS THERAPEUTICS, INC.

	By:	/s/ John W. Beck  John W. Beck Senior Vice President of Finance, Chief Financial Officer and Treasurer
Date: August 10, 2006

 

---

 

INDEX TO EXHIBITS

99.1         Press release of Metabasis Therapeutics, Inc. dated August 10, 2006.